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Abstract
Online haemodiafiltration (HDF) is increasingly used in clinical practice as a routine intermittent dialysis modality. It is well
known that renal impairment and renal replacement therapy can substantially affect the pharmacokinetic behaviour of
several drugs. However, surprisingly few data are available on the need for specific dose adjustments during HDF. Due to
convection, drug clearance may be increased during HDF as compared with standard haemodialysis. This may be of particu-
lar interest in patients undergoing anti-infective therapy, since under-dosing may compromise patient outcomes and pro-
mote the emergence of bacterial resistance. Drug clearance during HDF is determined by (i) dialysis characteristics, (ii) drug
characteristics and (iii) patient characteristics. In this review, we will discuss these different determinants of drug clearance
during HDF and advise on how to adjust the dose of antibacterial, antimycotic and antiviral agents in patients undergoing
HDF. In addition, the possible added value of therapeutic drug monitoring is discussed. The review provides guidance for
optimization of anti-infective dosing regimens in HDF patients.
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Introduction
Online haemodiafiltration (HDF) is increasingly used in clinical
practice as a routine intermittent dialysis modality. During HDF,
diffusion—the working principle of haemodialysis (HD)—and
convection—the working principle of haemofiltration—are
combined to optimize clearance of uraemic toxins. Diffusion is
very efficacious for removal of components with low molecular
weight (MW). Convective transport is based on a pressure gradi-
ent between the blood and dialysate compartment in the dialy-
ser, resulting in a flux [or ultrafiltration (UF)] across the
membrane. Clearance by convection is directly related to the
magnitude of the convection volume and is less affected by MW
up to the range of 30–40 kDa. Hence, due to the convection com-
ponent, clearance of relatively large molecules is typically im-
proved in HDF as compared with standard HD. Three large
randomized controlled trials have suggested improved clinical
outcomes after long-term HDF as compared with low- or high-
flux HD, when large convection volumes are applied [1–3].
It is well recognized that renal impairment and renal replace-
ment therapy (RRT) can substantially affect the pharmacokinetics
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of a drug. Several studies investigating drug concentrations during
HD are available in the literature. However, practical dosing advice
for dialysis patients as mentioned in text books often originates
from studies in which traditional low-flux dialysers were used.
Such advice may lead to under-dosing when patients are treated
with high-flux HD or HDF. Switching patients from low-flux HD to
high-flux HD or HDF should trigger a reassessment of dosing regi-
mens, especially for drugs with a narrow therapeutic range.
Limited data are available regarding the need for add-
itional dose adjustments when solute removal is increased
during HDF as compared with HD, probably due to the fact
that HDF is a rather new development in dialysis practice.
Dosing regimens suitable for patients with normal renal func-
tion may result in drug accumulation in HDF patients.
Conversely, dosing regimens suitable for patients treated
with standard HD may result in subtherapeutic drug levels
due to enhanced clearance by HDF, possibly leading to under-
treatment. In addition, the emergence of bacterial resistance
could be promoted.
A solid understanding of the various determinants affecting
drug clearance by dialysis may help to judge the risk of under-
and overtreatment in order to optimize patient outcome. Drug
clearance during RRT is determined by (i) dialysis characteris-
tics, (ii) drug characteristics and (iii) patient characteristics. In
this review, we will discuss the different determinants of drug
clearance and provide recommendations for drug dosing in HDF
patients, in particular to optimize antibacterial, antimycotic
and antiviral therapy.
Determinants of drug clearance during
intermittent chronic dialysis
Dialysis characteristics
Dialysis characteristics that may affect drug clearance during
HDF include dialysis efficiency, treatment time and treatment
frequency (Table 1). Dialysis efficiency is dependent on both dif-
fusion and convection [4]. Drug removal by diffusion mainly de-
pends on the applied blood and dialysate flow rates and the
dialyser specifications. Drug removal by convection depends on
the convection volume, which is determined by several factors
that are described elsewhere [5] and include blood flow rate and
dialyser specifications. Major dialyser specifications that affect
drug clearance include the dialyser surface area, the dialyser UF
coefficient (KUF) and the membrane composition, as described
below.
Dialyser surface area
The surface area of the dialyser is the maximal area available
for blood contact and is directly related to the clearance of low
MW solutes [6].
Ultrafiltration coefficient
The KUF is defined as the amount of fluid per hour transferred
through the membrane per mmHg pressure gradient across
the membrane [7]. High-flux dialysers (KUF>20 mL/h/mmHg)
are more permeable resulting in improved drug clearance of
relatively high MW [8] as compared with low-flux dialysers
(KUF20 mL/h/mmHg). The addition of a convection compo-
nent results in a further improvement of drug clearance.
High-flux dialysers can be used for high-flux HD or online
HDF; low-flux dialysers can only be used for low-flux HD.
Dialyser flux has increased over the years due to technical
advances. Most dialysis centres now routinely perform high-
flux HD.
Dialyser membrane composition
During dialysis treatment, typically with high UF rates as during
HDF, a protein layer is formed on the dialyser membrane [4, 9].
The extent to which this occurs depends on the dialyser mem-
brane composition. Generally, this will negatively affect solute
removal since the permeability of the membrane will decrease.
Conversely, adsorption may contribute to increased drug clear-
ance, especially if the drug is highly protein bound. For ex-
ample, in an in vitro HDF experiment it was shown that
teicoplanin could be eliminated by adsorption to the membrane
[10]. The relevance of this observation for clinical practice is not
clear.
Increasing the dialysis treatment time—as in nocturnal dia-
lysis—or increasing dialysis frequency—as in short daily dialy-
sis—may have a substantial effect on removal of a drug.
Generally, drug removal is increased by increasing treatment
time and/or frequency. Drug dosing considerations for noctur-
nal and short daily dialysis are discussed extensively elsewhere
[11]. Very few studies have investigated solute clearances dur-
ing nocturnal HDF. None of these studies addressed drug
clearance.
Drug characteristics
The extent to which a drug is affected by dialysis is determined
primarily by several physicochemical characteristics of the
drug, including MW, protein binding, volume of distribution
(Vd) and plasma clearance.
Molecular weight
The movement of drugs or other solutes through the membrane
is largely determined by the size of the molecules in relation to
the pore size of the dialysis membrane. Larger molecules (arbi-
trarily defined at >500 Da) can only be removed with high-flux
dialysers. HDF is exclusively performed with high-flux dialysers.
Moreover, the addition of convection (as opposed to low- or
high-flux HD) may lead to more efficient removal of larger
molecules.
Table 1. Determinants of drug clearance during HDF
Dialysis characteristics Convection volume
Dialyser specifications
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Protein binding
Only the unbound fraction of a drug is cleared by dialysis.
Hence, drugs with a high degree of protein binding are not effi-
ciently eliminated by dialysis. Convective as well as diffusive
transport of solutes across artificial kidney membranes is lim-
ited by protein binding.
Volume of distribution
A drug with a large Vd is distributed widely throughout tissues
and is present in relatively small amounts in the blood. Thus, a
larger Vd is related to less-efficient drug removal during inter-
mittent RRT.
Route of elimination
Removal of a drug from the systemic circulation can occur by
renal and nonrenal clearance. Renal clearance includes glom-
erular filtration, active secretion and absorption. Impairment of
renal clearance may for some drugs be limited to reduced glom-
erular filtration, but for other drugs, also disruption of active
tubular secretion (e.g. piperacillin, flucloxacillin) or tubular ab-
sorption may be comprised. In general, if for a particular drug,
nonrenal clearance is large compared with renal clearance, the
impact of RRT on drug removal is limited. However, when a
drug is excreted by glomerular filtration but actively reabsorbed
by the tubule, this drug is not renally cleared, but RRT will in-
duce enhanced removal of this drug from the systemic
circulation.
Besides pharmacokinetic characteristics, the pharmacody-
namic characteristics of a drug also play a role when deciding
how the dose should be adjusted when HDF is performed. Anti-
infective activity of a drug can depend on: (i) the time during
which the antimicrobial agent concentration is maintained
above the minimum inhibitory concentration of the pathogen
(T>MIC, e.g. b-lactam antibiotics) also known as time-
dependent; (ii) the ratio between the peak plasma concentration
and the MIC (Cmax/MIC, e.g. aminoglycosides) also known as
concentration-dependent; or on (iii) the ratio between the area
under the concentration-time curve (AUC) and the MIC (AUC/
MIC, e.g. vancomycin).
Notably, not only the parent drug but also active or toxic me-
tabolites should be taken into consideration. For instance, only
trace amounts of oseltamivir are eliminated in the urine, but
since its active metabolite oseltamivir carboxylate (OC) is
renally eliminated, oseltamivir dose adjustments are indicated
in patients with renal impairment and on dialysis [12].
Patient characteristics
Besides a reduction of glomerular filtration, renal impairment
may also affect other pharmacokinetic processes including ab-
sorption, distribution, metabolism and elimination.
Absorption may be decreased due to uraemic neuropathy,
an interaction with concomitant medication or intestinal
oedema.
Distribution, indicated by Vd, may be increased in case of
sepsis, due to fluid shifts from the intravascular compartment
to the interstitial space. Also, reduced protein binding, for in-
stance due to hypoalbuminaemia, may result in a larger
amount of free drug that may distribute into the tissues, leading
to a higher Vd and enhanced clearance.
Oxidative metabolic pathways for certain drugs may be
accelerated; other metabolic functions such as acetylation,
hydrolysis and reduction may be reduced. These concepts are
elucidated into more detail by Swan and Bennett [13].
Residual kidney function can be an important contributor to
drug clearance [14]. The presence of residual kidney function
may especially affect drugs that are actively secreted or re-
absorbed by the tubule.
Next to renal impairment, RRT can also affect patient char-
acteristics, such as albumin loss during dialysis. Although it has
been reported that albumin loss in the dialysate is significantly
greater during HDF compared with HD [15], albumin levels are
shown to be similar in HDF and HD patients [2, 16].
Pharmacokinetics and pharmacodynamics of
anti-infective agents during HDF
The various categories of anti-infective drugs (antibacterial,
antimycotic and antiviral drugs) include a wide variety of drug
characteristics. While data on conventional HD are available for
a selection of anti-infective drugs, removal by HDF has typically
not been investigated. An additional effect on drug clearance
due to convection during HDF (as opposed to low- or high-flux
HD) can be anticipated for compounds with a relatively high
MW, provided that protein binding is low and Vd is small. In
contrast, for low MW drugs HDF will not result in increased
clearance, since their removal during RRT is not typically im-
pacted by convection but mostly driven by diffusion. In Figure 1,
a systematic evaluation of drug characteristics is presented that
can help identify with which drugs to anticipate increased
clearance by HDF.
Following careful selection of a dosing regimen to initiate
anti-infective therapy during HDF, treatment may be further
optimized by therapeutic drug monitoring (TDM). TDM aims at
improving clinical outcome by individual dose-adjustments
based on measured drug concentrations in biological fluids.
TDM can be of high value for drugs with a small therapeutic
window and large inter-individual differences in pharmacokin-
etics. Furthermore, the amount of drug removal during an HDF
session can be calculated, based on drug concentrations of sam-
ples collected pre- and post-filter at several time points. This
concept is elucidated in more detail by Zandvliet et al. [17].
The most relevant drug characteristics, the anticipated add-
itional effect of convection, dosing suggestions and advice on
whether to apply TDM are listed in Table 2.
Aminoglycosides
Aminoglycosides are hydrophilic agents characterized by low
Vd, low protein binding and almost complete renal clearance.
These characteristics explain their rapid and consistent extra-
corporeal clearance during RRT. Netilmicin was studied by
Basile et al. in 1985, where clearance based on low-volume HDF
was compared with standard low-flux HD. From this study, it
appeared that a markedly increased clearance was observed by
the implementation of a high-flux filter and a high UF flow rate
[19]. Sombolos et al. [18] observed increased removal of gentami-
cin in a small study comparing online HDF with low-flux HD.
Given their relatively high MW, similar effects of convective
transport can be anticipated for the other aminoglycosides, es-
pecially for amikacin and streptomycin.
Aminoglycosides are characterized by concentration-
dependent bacterial killing; their effectiveness improves with
higher peak drug concentrations. The risk of aminoglycoside
toxicity (nephro- and oto-), has been associated with elevated
trough concentrations (Cmin), where Cmin for gentamicin and
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tobramycin should be <1 mg/L and for amikacin<5 mg/L.
Therefore, administering an aminoglycoside prior to dialysis
should theoretically allow the achievement of a high peak con-
centration (thereby enhancing bacterial killing), while subse-
quent early dialytic clearance should help to minimize the AUC
and trough concentrations (thereby limiting toxicity) [32].
However, this point is controversial in the literature, where the
Renal Drug Handbook [30] and the Kidney Disease Program [31]
advise to administer aminoglycosides after dialysis, presumably
based on older studies [33], and more recent studies indicate
that aminoglycosides should be administered prior to dialysis
[34, 35]. Unfortunately, for most patients with renal impairment,
also with RRT, attaining both adequate peak and trough concen-
trations is unlikely. Therefore, treatment with aminoglycosides
is discouraged. When there is no other treatment option, the
authors advise to administer aminoglycosides prior to dialysis,
where peak and trough concentrations should be measured to
optimize the patients’ dosing regimen.
Glycopeptides
Glycopeptides are hydrophilic antimicrobials with a very high
MW, which prevents removal during low-flux HD. However, gly-
copeptides are reported to be partly removed by high-flux HD
[20, 21]. Sombolos et al. [22] observed subtherapeutic vanco-
mycin concentrations in online HDF patients, even when an-
uric, after treatment with 15 mg/kg during the last hour of a 4-h
dialysis session. In coherence with the drug characteristics,
these findings suggest that teicoplanin and vancomycin may be
efficiently removed by online HDF.
The effectiveness of glycopeptides improves with a higher
AUC. Therefore, glycopeptides should be administered at the
end of dialysis or during the last hour of the dialysis, avoiding
early dialytic clearance. TDM, in the form of AUC estimation
(target AUC/MIC400 [36, 37]) with the aid of Bayesian feedback
[38] starting from the first dose, is strongly advocated for pa-
tients undergoing HDF.
b-lactams
b-lactam antibiotics (penicillins, cephalosporins and carbape-
nems) are hydrophilic compounds, with a low Vd and a pre-
dominant renal clearance. Most b-lactam antibiotics have a MW
below 500 Da. The degree of protein binding differs between the
different compounds, ranging from below 10% to above 90%.
Consequently, not all b-lactam antibiotics are efficiently
removed by RRT.
As opposed to the other penicillins, piperacillin has a rela-
tively high MW of 517.6 Da and low protein binding. Therefore,
the addition of convection to diffusion might increase its clear-
ance. Indeed, piperacillin clearance was larger during online
HDF as compared with historical data from patients who were
treated with conventional HD [23].
Ceftazidime and ceftriaxone both have a MW >500 Da. For
ceftazidime, increased drug removal during HDF is anticipated.
For ceftriaxone, due to its high protein binding (85–95%), extra-
corporeal clearance by HDF is less likely.
From a pharmacokinetic study on doripenem (MW 420.5 Da,
carbapenem group) in patients with sepsis who were treated
with high-volume HDF, it appeared that a substantial amount
of doripenem was eliminated [26].
The effectiveness of b-lactam antibiotics in clinical studies is
suggested to be time-dependent: it depends mainly on the dur-
ation of the presence of the agent at a concentration superior to
the target pathogen’s MIC, T>MIC [39–41]. Therefore, intraven-
ously administered b-lactam antibiotics should be administered
post-dialysis, avoiding early dialytic clearance. When an analyt-
ical assay is available, TDM can be applied to guide dosing opti-
mization in case of difficult to treat infections where high
doses, and thus high drug concentrations, are applied.
Sulfonamides and trimethoprim
Trimethoprim is lipophilic and has a large Vd. Sulfamethoxazole
and sulfadiazine, however, are hydrophilic and have a smaller Vd.
<400 Da





























Fig. 1. Systematic evaluation of drug characteristics to assess the potential increment of drug clearance by convection.
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All three compounds are moderately protein bound, mainly
renally cleared and have a MW 250 Da. These compounds will
be substantially cleared by HD, but no additional clearance
by HDF is expected. The major metabolite of sulfamethoxazole,
N-4-acetyl sulfamethoxazole, is primarily renally cleared and
has been demonstrated to accumulate in patients with renal
failure [42]. Sulfonamides and trimethoprim display concentra-
tion dependent killing (AUC/MIC) and should be administered
after dialysis, when administered intravenously. TDM of sulfa-
methoxazole and its main metabolite may be considered, espe-
cially in dialysis patients who are treated for Pneumocystis
jiroveci pneumonia (PJP) with high doses of co-trimoxazole [43].
Macrolides
Macrolides are lipophilic agents, with a large Vd (due to accu-
mulation in neutrophils), moderate to high degree of protein
binding and low to moderate renal clearance. Therefore, both
HD and HDF are not expected to efficiently remove macrolides
from the plasma. Toxicity of these agents in patients with renal
failure has been observed. The dose should be reduced based on
renal function [44].
Quinolones
Fluoroquinolones are lipophilic agents, with large Vd and a rela-
tively low MW. Therefore, these agents will only be marginally
cleared by HD, and no additional clearance by HDF is expected.
Other antibiotics
Colistin is administered as an inactive prodrug, colistin metha-
nesulfonate (CMS), which is mostly excreted unchanged in the
urine (70%) and partly converted to the active colistin. Renal ex-
cretion of colistin is negligible. As a result, in patients with renal
impairment, a greater fraction of the administered CMS dose
may be converted into colistin, leading to increased plasma
concentrations of colistin. Both CMS and colistin exhibit a small
Vd and moderate protein binding. Due to the high MW of CMS,
additional clearance from HDF is to be expected. Since CMS is a
mixture of approximately 30 different components, bioanalyti-
cal analysis of this drug is complicated and there is no readily
available assay for TDM purposes [45]. For severely ill patients
with infections caused by multi-resistant Gram-negative bac-
teria, a loading dose of 9 million IU followed by 2 million IU
twice daily is recommended in HDF patients [28].
Metronidazole is a lipophilic compound with a moderate Vd.
It exhibits a low degree of protein binding and is about 20%
renally cleared. Metronidazole is to some extent removed by
dialysis and based on its low MW (171.2 Da), no additional re-
moval by HDF compared with HD is anticipated.
Linezolid is a rather hydrophilic compound, with a relatively
small Vd, moderate protein binding and approximately 30% is
renally cleared. Linezolid is to some extent removed by dialysis,
although based on its low MW (337.3 Da), no additional removal
by HDF compared with HD is anticipated.
Successful treatment outcome is associated with AUC/MIC
and T > MIC [46]; linezolid should, therefore, be administered
after dialysis. When TDM is available, trough concentrations
(target Cmin 2–6 mg/L [47, 48]) can be measured to guide dosing.
Daptomycin is a hydrophilic compound, with a very high
MW (1620.7 Da) and high protein binding, and is predominantly
cleared by the kidneys. Due to its high MW, daptomycin is not
removed when low-flux HD is applied. When using HDF, some
extra clearance is to be anticipated. TDM assays are not widely
available and there is no clear target concentration defined, di-
minishing the value of TDM in these patients.
Triazole antimycotics
Fluconazole is a hydrophilic compound with a small Vd, low de-
gree of protein binding and predominant renal clearance.
Fluconazole is substantially cleared by HD; due to its MW of 306.3
Da no additional clearance by HDF is to be anticipated. The phar-
macokinetic/pharmacodynamic index related to efficacy is AUC/
MIC, therefore fluconazole should be administered after dialysis.
Itraconazole, voriconazole and posaconazole are lipophilic
compounds with a high degree of protein binding and are only
very marginally cleared by the kidneys. Therefore, HD and also
HDF will have no large effect on clearance of these drugs. Hafner
et al. [29] conducted a clinical trial and indeed demonstrated that
only a limited proportion of the administered voriconazole dose
was removed during a 6-h treatment with HD (12.7%) or online
HDF (13.1%). Since pharmacokinetics of voriconazole are shown
to be unpredictable and the added value of TDM-guided dosing of
voriconazole is demonstrated in a prospective clinical trial [49],
TDM is advised during treatment and prophylaxis. Trough sam-
ples should be taken 2 days after onset of treatment and a range
of 2–6 mg/L should be taken as a reference [50, 51].
Other antimycotics
Caspofungin exhibits a small Vd, but also a high degree of pro-
tein binding and very limited renal clearance; removal by HD or
HDF will be negligible.
Flucytosine exhibits a low Vd, low degree of protein binding,
is mainly renally cleared and will, therefore, be removed by HD.
Due to its limited MW (129.1 Da), no additional removal by HDF
is anticipated. The effectiveness of flucytosine is suggested to
be time-dependent. Therefore, flucytosine should be adminis-
tered post-dialysis, avoiding early dialytic clearance. TDM, in
the form of peak levels to reduce toxicity (<100 mg/L) and
trough levels to avoid resistance (>25 mg/L, before dialysis)
starting from the first dose, is strongly advocated for patients
undergoing HDF [52].
Anidulafungin exhibits a large Vd, high degree of protein
binding and very limited renal clearance; removal by HD or HDF
will be negligible.
Antiviral agents
Aciclovir and ganciclovir both have a low MW, low Vd and low
degree of protein binding, and are predominantly renally
cleared. Consequently, these agents are substantially cleared by
HD and HDF, where no additional clearance of HDF compared
with HD is to be anticipated. Aciclovir and ganciclovir should be
administered post-dialysis, to avoid early dialytic clearance.
Oseltamivir is considered to be a prodrug, which is converted
to the active metabolite OC. Oseltamivir itself is not renally
cleared; OC, on the contrary, is approximately 99% renally
cleared. It also exhibits a low Vd and a low degree of protein
binding and is, therefore, substantially cleared by HD and HDF,
where no additional clearance of HDF compared with HD is to
be anticipated. Oseltamivir should be administered post-
dialysis, to avoid early dialytic clearance.
Conclusions
Intermittent HDF is increasingly used in routine dialysis prac-
tice. Only a few clinical pharmacokinetic studies in HDF
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patients treated with anti-infective agents have been published.
Especially for patients with severe infections adequate dosing
regimens are essential and should be individualized based on
residual clearance and mode of dialysis. Incremented drug
clearance during HDF as compared with HD, due to convective
transport, can be anticipated for substances with a high MW,
low to moderate protein binding, small Vd and moderate to
high degree of renal clearance.
For drugs with a narrow therapeutic range, concentration
measurements may result in further individualization of the
dosing regimen. Particularly for the aminoglycosides and glyco-
peptides, with established therapeutic ranges and widely avail-
able analytical assays, TDM is strongly recommended for
treatment optimization.
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